If your current medications arent doing enough to manage your obstructive hypertrophic cardiomyopathy (HCM), your cardiologist may recommend mavacamten (Camzyos). The drug helps your heart relax, ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

The Emotional Impact of Obstructive HCM Practical Coping Strategies to Try Integrate Emotional Health Into Daily Life The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very ...

Hypertrophic cardiomyopathy is the most common genetic heart disease, with prevalence estimates from one in 200 to one in 500. However, the true prevalence is poorly understood due to likely ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

Cytokinetics, Incorporated announced five presentations related to aficamten at the upcoming European Society of Cardiology Congress 2025 in Madrid, highlighting positive topline results from the ...

The trial met its primary endpoint demonstrating the superiority of aficamten in improving peak exercise capacity compared with metoprolol. Topline results were announced from a phase 3 study ...

You can manage the risks of hypertrophic cardiomyopathy (HCM) with treatment and lifestyle changes. Here’s how to make the most of your next medical checkup. HCM is a genetic condition in which the ...